InvestorsHub Logo
Followers 828
Posts 119591
Boards Moderated 14
Alias Born 09/05/2002

Re: DewDiligence post# 1875

Wednesday, 05/06/2020 4:16:39 PM

Wednesday, May 06, 2020 4:16:39 PM

Post# of 2957
ENTA discontinues EDP-305 for PBC indication following phase-2 miss on primary endpoint:

https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Announces-Results-of-INTREPID-Study-of-EDP-305-for-the-Treatment-of-Primary-Biliary-Cholangitis/default.aspx

PBC is a small indication and EDP-305 is a bad drug, so ENTA’s discontinuing this program is entirely justifiable.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News